CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition

Cited by papers we hold 6

• Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response · 2022
  No notice
• The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis · 2022
  No notice
• The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment · 2022
  No notice
• CXCL1: Gene, Promoter, Regulation of Expression, mRNA Stability, Regulation of Activity in the Intercellular Space · 2022
  No notice
• Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis · 2020
  No notice
• Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.